Recursion Pharmaceuticals (NASDAQ:RXRX - Free Report) had its target price cut by Needham & Company LLC from $17.00 to $16.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have a buy rating on the stock.
Separately, KeyCorp cut their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an overweight rating for the company in a report on Thursday, July 11th.
View Our Latest Analysis on RXRX
Recursion Pharmaceuticals Stock Performance
Shares of RXRX traded down $0.35 during trading hours on Friday, hitting $6.29. 8,665,672 shares of the company were exchanged, compared to its average volume of 6,060,540. The company has a market cap of $1.49 billion, a PE ratio of -3.93 and a beta of 0.83. The firm's 50 day moving average is $8.12 and its 200-day moving average is $9.33. Recursion Pharmaceuticals has a 52 week low of $4.97 and a 52 week high of $15.74.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The business had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. During the same period in the prior year, the firm posted ($0.38) EPS. Recursion Pharmaceuticals's revenue for the quarter was up 30.9% on a year-over-year basis. As a group, equities analysts forecast that Recursion Pharmaceuticals will post -1.56 earnings per share for the current fiscal year.
Insider Activity
In other news, CEO Christopher Gibson sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $8.42, for a total value of $421,000.00. Following the sale, the chief executive officer now directly owns 758,738 shares in the company, valued at approximately $6,388,573.96. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, COO Tina Marriott sold 3,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.78, for a total transaction of $26,340.00. Following the sale, the chief operating officer now directly owns 535,457 shares in the company, valued at approximately $4,701,312.46. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $8.42, for a total value of $421,000.00. Following the sale, the chief executive officer now owns 758,738 shares in the company, valued at $6,388,573.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 243,682 shares of company stock worth $1,945,468. Company insiders own 15.75% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Arizona State Retirement System raised its stake in Recursion Pharmaceuticals by 8.5% during the 4th quarter. Arizona State Retirement System now owns 39,926 shares of the company's stock worth $394,000 after buying an additional 3,125 shares during the period. International Assets Investment Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1,423.8% during the fourth quarter. International Assets Investment Management LLC now owns 16,762 shares of the company's stock worth $1,700,000 after acquiring an additional 15,662 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Recursion Pharmaceuticals by 161.2% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company's stock valued at $90,749,000 after buying an additional 5,680,656 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Recursion Pharmaceuticals by 32.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 40,658 shares of the company's stock valued at $401,000 after purchasing an additional 10,033 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its stake in shares of Recursion Pharmaceuticals by 1,508.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 11,759 shares of the company's stock worth $116,000 after buying an additional 11,028 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.
Recursion Pharmaceuticals Company Profile
(Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
- Five stocks we like better than Recursion Pharmaceuticals
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- The Cannabis Sector: Profitability Takes Center Stage
- Investing In Preferred Stock vs. Common Stock
- Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Buy the Dip in e.l.f. Beauty: Analysts Point to a New High
→ Have you ever… (From DTI) (Ad)
Should you invest $1,000 in Recursion Pharmaceuticals right now?
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
5G Stocks: The Path Forward is Profitable
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
